Regenxbio SEC Filings

REGENXBIO Inc. reported Q3 2025 results. Total revenue was $29.7 million, driven by $23.6 million of license and royalty revenue and $6.1 million of service revenue. For the nine months, revenue reached $140.1 million.

The company posted a Q3 net loss of $61.9 million and a basic and diluted net loss per share of $1.20. Interest expense rose to $13.2 million in the quarter, reflecting royalty financing activity. Operating expenses were $82.1 million in Q3, led by $56.1 million in research and development and $20.3 million in general and administrative costs.

Cash, cash equivalents and marketable securities totaled $302.0 million as of September 30, 2025. Royalty monetization liabilities increased to $191.6 million, including a new 2025 Royalty Bond initially funded with $150.0 million (net proceeds $144.5 million). Deferred revenue rose to $34.4 million current and non-current combined, aligned with recent collaboration activity and the new presentation separating service revenue. Shares outstanding were 50,623,086 as of October 31, 2025.

Simpson Curran, who is listed as both Chief Executive Officer and a Director of REGENXBIO Inc. (RGNX), reported an open-market sale of company common stock under a pre-existing trading plan. On 10/09/2025 the reporting person disposed of 20,811 shares at a weighted average price of $12.62 per share, with the filing noting the sale was effected pursuant to a Rule 10b5-1 trading plan and executed in multiple trades at prices ranging from $12.50 to $12.84.

Following this reported transaction the reporting person beneficially owned 216,162 shares. The Form 4 was signed via attorney-in-fact on 10/10/2025.

REGENXBIO, Inc. (RGNX) filed a Form 144 notifying the proposed sale of 20,811 common shares with an aggregate market value of $254,310.42, scheduled for 10/09/2025 and to be executed on the NASDAQ. The shares were acquired as Restricted Stock Units on 01/01/2025, and the filer indicates the securities were granted by the issuer.

The filing discloses recent Rule 10b5-1 sales by the same person: 7,624 shares sold on 09/29/2025 for $76,434.41 and 7,734 shares sold on 09/10/2025 for $77,530.26. Outstanding shares are listed as 50,514,216, making the proposed sale a small fraction of total outstanding equity.

Simpson Curran, serving as Chief Executive Officer and a director of REGENXBIO Inc. (RGNX), reported a sale of 7,624 shares of the issuer's common stock on 09/29/2025. The sale was effected under a Rule 10b5-1 trading plan and executed in multiple trades at prices ranging from $10.00 to $10.08, with a weighted average sale price of $10.03. Following the reported transaction, the reporting person beneficially owned 236,973 shares, held directly. The Form 4 was signed by an attorney-in-fact, Patrick J. Christmas, on 10/01/2025. No derivative transactions or other securities classes were reported in this filing.

REGENXBIO Inc. (RGNX) filed a Form 144 notifying the proposed sale of 15,358 shares of its common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $151,890.62 and an approximate planned sale date of 09/10/2025 on NASDAQ.

The shares were acquired as Restricted Stock Units from the issuer on 01/01/2023 and total outstanding shares are reported as 50,514,216, making the planned sale approximately 0.03% of outstanding stock. The filing affirms the signer does not possess undisclosed material adverse information and indicates no securities were sold in the past three months by the reporting person.

Craig Malzahn, Chief Technology Officer of REGENXBIO Inc. (RGNX), reported a non-derivative transaction dated 09/01/2025 in which 234 shares of common stock were disposed at a price of $8.93 per share. After the transaction he beneficially owned 17,585 shares directly. The filing states the 234 shares were withheld to pay taxes upon the vesting of restricted stock units originally granted on September 1, 2022, with the withholding amount calculated using the issuer's closing stock price on August 29, 2025. The form was signed via attorney-in-fact on 09/03/2025.

Chan Mitchell, the Chief Financial Officer of REGENXBIO Inc. (RGNX), reported a non-derivative disposition on 09/01/2025. The filing shows 4,901 shares of common stock were withheld to satisfy taxes upon the vesting of restricted stock units originally granted on September 16, 2024, using a withholding price of $8.93 (based on the closing price on August 29, 2025). After the withholding, the reporting person beneficially owns 53,968 shares directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/03/2025.

Redmile Group, LLC and related persons report a 9.99% beneficial position in REGENXBIO Inc. The filing shows Redmile Group, LLC and principal Jeremy C. Green each report shared voting and dispositive power over 5,062,477 shares, representing 9.9% of the class on a calculated basis. Those totals include 286,760 shares that could be issued upon exercise of pre-funded warrants but are limited by a Beneficial Ownership Limitation that prevents exercise that would cause ownership to exceed 9.99%. Redmile Biopharma Investments III, L.P. reports ownership of 3,733,796 shares (7.4%), comprised of 3,447,036 directly held shares plus warrants subject to the same blocker. All parties disclaim ownership except for pecuniary interest. The percentage base uses 50,388,693 outstanding shares as of June 9, 2025, plus the 286,760 potentially issuable Warrant shares.